Core Insights - Charlotte's Web Holdings, Inc. is establishing a Scientific Advisory Board to enhance its medical strategy and support R&D initiatives, expected to begin in September 2025 [1][3][5] Group 1: Company Overview - Founded over a decade ago, Charlotte's Web is a leader in hemp-derived CBD wellness products, emphasizing safety, research, and standardization [2] - The company originated from the development of full-spectrum hemp genetics, which has significantly influenced the hemp health and wellness sector [2] Group 2: Scientific Advisory Board - The Scientific Advisory Board will guide the company's research agenda, clinical initiatives, and the translation of botanical science into patient-centered solutions [1][3] - Dr. Marcel Bonn-Miller, a prominent cannabinoid researcher, will lead the board, bringing over 20 years of experience and numerous published research papers [4][5] Group 3: Medical Channel Strategy - The company aims to scale its medical channel strategy, focusing on product formulations and practitioner education to meet the growing demand for clinically relevant CBD solutions [3][5] - Initiatives include creating Continuing Medical Education (CME) content for healthcare professionals to address gaps in patient care related to pain, anxiety, and sleep issues [3][5] Group 4: Partnerships and Clinical Trials - Charlotte's Web is collaborating with DeFloria, Inc. and Ajna BioSciences PBC to develop AJA001, a full-spectrum CBD extract for treating irritability associated with autism spectrum disorder, which has received FDA approval for Phase 2 clinical trials [3]